Drugs / Pneumosil
Pneumosil
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT03896477 | Jul 2019 → Dec 2020 | streptococcal pneumonia | PATH | Completed | No outcome recorded |
| Phase 3 | NCT03197376 | Jun 2017 → Jun 2018 | streptococcal pneumonia | PATH | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06817421 | Jan 2026 → Mar 2028 expected | pneumococcal infection, pneumonia | Nick Fancourt | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04945681 | Nov 2022 → Jan 2025 overdue | pneumococcal infection | London School of Hygiene and Tropical Medicine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05175014 | Dec 2021 → Mar 2023 | — | Epicentre | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05140720 | Jan → Feb 2022 | streptococcal pneumonia | Vabiotech | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06879327 Background | May 2025 → Sep 2027 expected | malaria | PATH | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumosil | “The study will adopt a quasi-experimental design, with baseline and post-intervention surveys to evaluate changes in pneumococcal carriage, complemented by safety assessment in...” NCT04945681 ↗6“Safety and coverage of Pneumosil pneumococcal polysaccharide conjugate vaccine (10-valent PCV) in a camp for internally displaced persons in Somaliland.” PMID 41265006 ↗ Nov 2025 “campaigns consisting of a single full dose of a 10-valent PCV (Pneumosil), a single one-fifth dose of Pneumosil, or no campaign” PMID 39798587 ↗ Jan 2025 “Treatment Arm: Pneumosil” NCT06817421 ↗ |
| Known as | PCV10-SII | “PCV10-SII (PNEUMOSIL), a 10-valent PCV prequalified by the World Health Organization (WHO) in 2019, offers a cost-effective alternative.” PMID 42042812 ↗ Apr 20261“The 10-valent Pneumosil PCV (PCV10-SII) is currently licensed for use in children aged 6 weeks to 2 years.” PMID 41265006 ↗ Nov 2025 |
| Known as | Pneumococcal Polysaccharide Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879327 ↗ |
| Known as | SIIPL-PCV | “a novel ten-valent PCV (SIIPL-PCV) containing serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F” PMID 33516293 ↗ Jan 2021 |
| Modality | Vaccine | “a novel ten-valent pneumococcal conjugate vaccine” PMID 33516293 ↗ Jan 2021 |
| Route | Intramuscular | “Vaccines (0·5 mL SIIPL-PCV or 0·5 mL PHiD-CV) were administered at ages 6, 10, and 14 weeks by intramuscular injection.” PMID 33516293 ↗ Jan 2021 |